Ensifentrine is Phase III-ready asset targeting a vast market of underserved COPD patients, and we believe the company offers one of the best opportunities for investors in the UK Biotech space. We have high conviction on ensifentrine as an effective and safe potential therapy for COPD, and believe the current Phase III trial design gives a reasonable and achievable route to US regulatory approval. We update forecasts to reflect the upside upon success, and assume short-term funding of $130m
08 Jun 2020
Phase III ready to capitalise vast COPD market
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Phase III ready to capitalise vast COPD market
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
08 Jun 2020 -
Author:
Edward Thomason -
Pages:
3
Ensifentrine is Phase III-ready asset targeting a vast market of underserved COPD patients, and we believe the company offers one of the best opportunities for investors in the UK Biotech space. We have high conviction on ensifentrine as an effective and safe potential therapy for COPD, and believe the current Phase III trial design gives a reasonable and achievable route to US regulatory approval. We update forecasts to reflect the upside upon success, and assume short-term funding of $130m